rAAV2tYF-PR1.7-hCNGB3 / Beacon Therapeutics - LARVOL DELTA

Phase update (GlobeNewswire) - Preclinical➔P2, Ophthalmology

Phase shift

AGTC announces reaching enrollment milestones in phase 1/2 clinical trials (agtc Press Release) - "Applied Genetic Technologies Corporation...today announced that it has achieved enrollment milestones in two of its Phase 1/2 clinical trials. The company completed enrollment of the dose escalation portion of the achromatopsia (ACHM) CNGB3 trial, which is evaluating the safety and efficacy of its product candidate (rAAV2tYF-PR1.7-hCNGB3) for the treatment of ACHM caused by mutations in the CNGB3 gene. The company also completed enrollment in the expansion group, which includes pediatric patients, of its product candidate (rAAV2tYF-GRK1-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene."

Enrollment status